NCT00590720 - A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

October 31, 2009

Conditions

Asthma

Interventions

BIOLOGICAL

MEDI528 50 mg

MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks

OTHER

PLACEBO

Placebo administered as a subcutaneous injection twice weekly for 4 weeks

Trial Locations (12)

Univ. of South Florida, Asthma, Allergy & Immunology Clinical Research Unit, Tampa

Bernstein Clinical Research Center, Cincinnati

Sneeze,Wheeze & Itch Associates, LLC, Normal

The Clinical Research Center, LLC, St Louis

Creighton University, Omaha

National Jewish Medical and Research Center, Denver

Institute of Healthcare Assessment, Inc, San Diego

Waterbury Pulmonary Associates, Waterbury

Northeast Medical Research Associates, Inc, No. Dartmouth

Calgary COPD & Asthma Program, Calgary

UHN- Toronto Western Hospital, Toronto

Centre de Recherche Appliquee en Allergie de Quebec, Québec